CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight
The CD19 inhibitors market is projected to expand substantially in the coming years. This growth is driven by a rising number of patients diagnosed with conditions such as NHL, ALL, NMOSD, IgG4-RD, SLE, multiple sclerosis, and other related diseases; increasing awareness of CD19-targeted therapies; and a growing pipeline of investigational drugs such as Obexelimab (Zenas BioPharma), GLPG5101 (Galapagos NV), IKS 03 (Iksuda Therapeutics), ANKTIVA + CD19 t-haNK (ImmunityBio), NKX019 (Nkarta), CABA-201 (Cabaletta Bio), CLN-978 (Cullinan Therapeutics), ATA3219 (Atara Bio), KITE-363, KITE-753, KITE-197, and KITE-363 (Gilead), PL001 (Pell Bio-Med), and others advancing through clinical trials.
LAS VEGAS, March 10, 2026 /PRNewswire/ -- DelveInsight's CD-19 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Non-Hodgkin Lymphomas (NHL), Acute Lymphoblastic Leukemia (ALL), Neuromyelitis Optica Spectrum Disorder (NMOSD), Immunoglobulin G4-related Disease (IgG4-RD), Systemic Lupus Erythematosus (SLE), Multiple Sclerosis, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging CD-19 inhibitors, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).
Key Takeaways from the CD-19 Inhibitors Market Report
Discover how big will the CD-19 inhibitors market be by 2034 @ https://www.delveinsight.com/sample-request/cd19-market-forecast?utm_source=cision&utm_medium=pressrelease&utm_campaign=scpr
Key Factors Driving the CD-19 Inhibitors Market
Ramandeep Singh, Senior Consultant, Forecasting and Analytics at DelveInsight, noted that this is an exciting new class of agents with great potential for development. The maturation of current studies over the next few years will lead to a better understanding of CD19 inhibitors and define their role in the therapy of cancers and autoimmune disorders.
CD-19 Inhibitors Market Analysis
Learn more about which companies dominate the CD-19 / CAR-T space @ CD-19 Inhibitors Analysis
CD-19 Inhibitors Competitive Landscape
Some of the emerging CD-19 inhibitors in development include Obexelimab (Zenas BioPharma), GLPG5101 (Galapagos NV), IKS 03 (Iksuda Therapeutics), ANKTIVA + CD19 t-haNK (ImmunityBio), NKX019 (Nkarta), CABA-201 (Cabaletta Bio), CLN-978 (Cullinan Therapeutics), ATA3219 (Atara Bio), KITE-363, KITE-753, KITE-197, and KITE-363 (Gilead), PL001 (Pell Bio-Med), and others.
Zenas BioPharma's Obexelimab (XmAb5871) is a monoclonal antibody designed to bind CD19 through its variable region while engaging the inhibitory FcγRIIb receptor via Xencor's XmAb immune-inhibitor Fc domain. It is the first therapy Xencor knows of that specifically leverages FcγRIIb-mediated suppression. By strongly blocking B-cell activation without reducing B-cell numbers, Obexelimab stands apart from other B-cell–directed treatments and shows promise for a wide range of autoimmune conditions. It is currently in Phase III trials for Warm Autoimmune Hemolytic Anemia and IgG4-Related Disease, and is also being explored for Multiple Sclerosis and Systemic Lupus Erythematosus.
Galapagos' GLPG5101 is a next-generation anti-CD19/4-1BB CAR-T therapy delivered as a single fixed IV dose. Its safety, activity, and decentralized manufacturing feasibility are being investigated in the ATALANTA-1 Phase I/II trial in patients with relapsed or refractory non-Hodgkin lymphoma.
Cabaletta Bio's Rese-cel is a fully human CD19-targeting CAR-T therapy that incorporates a 4-1BB co-stimulatory domain. Cabaletta is evaluating it in the RESET Phase 1/2 programs for systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris, with potential for broader autoimmune applications.
The anticipated launch of these emerging therapies are poised to transform the CD-19 inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the CD-19 inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about how do diagnostics and early detection affect CD-19 therapy markets, visit @ CD-19 Inhibitors Treatment
Recent Developments in the CD-19 Inhibitors Market
What are CD-19 Inhibitors?
CD-19 inhibitors are a class of biological agents designed to block or eliminate cells that display the CD19 protein, a marker found almost exclusively on B-cells, including many malignant B-cells. By targeting this surface protein, CD-19 inhibitors are used in research and certain therapeutic strategies to help reduce abnormal or cancerous B-cell populations. They are most widely associated with advanced immunotherapies, such as monoclonal antibodies and engineered cell-based treatments, that rely on recognizing CD19 to guide an immune response. Because CD19 is present throughout most stages of B-cell development, inhibiting it can significantly influence immune activity, making these agents powerful but requiring carefully controlled clinical use.
CD-19 Inhibitors Epidemiology Segmentation
The CD-19 inhibitors market report is a comprehensive and specialized analysis, offering in-depth epidemiological insights for the study period 2020–2034 across the leading markets. The CD-19 inhibitors target patient pool is segmented into:
CD-19 Inhibitors Report Metrics
Details
Study Period
2020–2034
CD-19 Inhibitors Report Coverage
7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Key Indications Covered in the Report
Non-Hodgkin Lymphomas (NHL), Acute Lymphoblastic Leukemia (ALL), Neuromyelitis Optica Spectrum Disorder (NMOSD), Immunoglobulin G4-related Disease (IgG4-RD), Systemic Lupus Erythematosus (SLE), Multiple Sclerosis, and others
CD-19 Inhibitors Target Patient Pool Segmentation
Total Cases of Selected Indications for CD-19 Inhibitors, Total Eligible Patient Pool for CD-19 Inhibitors in Selected Indications, and Total Treated Cases in Selected Indications for CD-19 Inhibitors
Key CD-19 Inhibitors Companies
Zenas BioPharma, Galapagos NV, Iksuda Therapeutics, ImmunityBio, Nkarta, Cabaletta Bio, Cullinan Therapeutics, Atara Bio, Gilead, Pell Bio-Med, Autolus Therapeutics, Incyte Corporation, MorphoSys, and others
Key CD-19 Inhibitors
Obexelimab, GLPG5101, IKS 03, ANKTIVA + CD19 t-haNK, NKX019, CABA-201, CLN-978, ATA3219, KITE-363, KITE-753, KITE-197, KITE-363, PL001, AUCATZYL, MONJUVI, and others
Scope of the CD-19 Inhibitors Market Report
Discover what are the top drugs by sales or uptake rates @ CD-19 Inhibitors Clinical Trials
Table of Contents
1
CD-19 Inhibitors Market Key Insights
2
CD-19 Inhibitors Market Report Introduction
3
Key Highlights of The Report
4
Executive Summary Of CD-19 Inhibitors
5
Key Events
6
Epidemiology And Market Forecast Methodology
7
CD-19 Inhibitors Market Overview At A Glance
7.1
Market Share (%) Distribution of CD-19 Inhibitors By Therapies in 2020
7.2
Market Share (%) Distribution of CD-19 Inhibitors By Therapies in 2034
7.3
Market Share (%) Distribution of CD-19 Inhibitors By Indications in 2020
7.4
Market Share (%) Distribution of CD-19 Inhibitors By Indications in 2034
8
Background And Overview
9
Epidemiology And Patient Population
9.1
Key Findings
9.2
Assumptions And Rationale
9.3
Total Cases by Indication in the 7MM
9.4
Total Eligible Patient Pool by Indications in the 7MM
9.5
Treatable Cases by Indication in the 7MM
9.4.1
United States
9.4.1.1
Cases by Indication in the United States
9.4.1.2
Total Eligible Patient Pool by Indications in the United States
9.4.1.3
Treatable Cases by Indication in the United States
9.4.2
EU4 and the UK
9.4.3
Japan
10
Marketed CD-19 Inhibitors
10.1
Key Competitors
10.2
AUCATZYL (obecabtagene autoleucel): Autolus Therapeutics
10.2.1
Product Description
10.2.2
Regulatory Milestones
10.2.3
Other Developmental Activities
10.2.4
Ongoing Clinical Development
10.2.5
Safety and Efficacy
10.3
MONJUVI (tafasitamab-cxix): Incyte Corporation/ MorphoSys
11
Emerging CD-19 Inhibitors
11.1
Key Competitors
11.2
Obexelimab: Zenas BioPharma
11.2.1
Product Description
11.2.2
Other Development Activities
11.2.3
Clinical Development
11.2.3.1
Clinical Trials Information
11.2.4
Safety and Efficacy
11.3
GLPG5101: Galapagos NV
11.4
IKS 03: Iksuda Therapeutics
List to be continued…
12
CD-19 Inhibitors Market: The 7MM Analysis
12.1
Key Findings
12.2
CD-19 Inhibitors Market Outlook
12.3
Key CD-19 Inhibitors Market Forecast Assumptions
12.4
Total Market Size of CD-19 Inhibitors in the 7MM
12.5
Market Size of CD-19 Inhibitors By Therapies In the 7MM
12.6
United States CD-19 Inhibitors Market
12.6.1
Total Market Size of CD-19 Inhibitors in the United States
12.6.2
Market Size of CD-19 Inhibitors By Therapies in the United States
12.7
EU4 and the UK CD-19 Inhibitors Market
12.8
Japan CD-19 Inhibitors Market
12.8.1
Total Market Size of CD-19 Inhibitors in Japan
12.8.2
Market Size of CD-19 Inhibitors By Therapies in Japan
13
CD-19 Inhibitors Market Unmet Needs
14
CD-19 Inhibitors Market SWOT Analysis
15
KOL Views on CD-19 Inhibitors
16
CD-19 Inhibitors Market Access and Reimbursement
16.1
United States
16.2
EU4 and the UK
16.3
Japan
17
Bibliography
18
CD-19 Inhibitors Market Report Methodology
Related Reports
Non-Hodgkin's Lymphoma Market
Non-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key non-hodgkin's lymphoma companies, including ADC Therapeutics, Bristol-Myers Squibb, Roche, Amgen, Johnson & Johnson, Celgene Corp., Mesoblast, Genmab, Novartis, Teva Pharmaceutical Industries, Karyopharm Therapeutics, AB Science, Genentech, Eli Lilly and Company, Rafael Pharmaceuticals, IO Biotech, ImmuneOnco Biopharma, Chongqing Precision Biotech, Rhizen Pharmaceuticals, Nanjing Legend Biotech, Tokalas, Arvinas, MorphoSys AG, Shanghai Genechem, Guiguidan Biomedicine (Zhongshan), Corvus Pharmaceuticals, Evive Biotech, Kite Pharma, Pfizer, Gilead Sciences, TG Therapeutics, AstraZeneca, Bayer HealthCare Pharmaceuticals, Secura Bio, BeiGene, Xynomic Pharmaceuticals, Merck & Co. Inc., Epizyme, Nordic Nanovector, Artiva Biotherapeutics, Inc., Timmune Biotech, Forty Seven, Acerta Pharma, BioInvent International, Adagene, Juventas Cell Therapy, SystImmune, Molecular Templates, Apollomics, MEI Pharma, and others.
Neuromyelitis Optica Spectrum Disorder Market
Neuromyelitis Optica Spectrum Disorder Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NMOSD companies, including RemeGen, Alexion Pharmaceuticals, Reistone Biopharma, Nihon Pharmaceutical, Harbour BioMed, Bio-Thera Solutions, Abide Therapeutics, Bionure, TG Therapeutics, ENDECE, Boston Pharmaceuticals, NovelMed, AstraZeneca, Amgen, Roche, and others.
Systemic Lupus Erythematosus Market
Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key SLE companies including Biogen, Novartis, MorphoSys, Idorsia Pharmaceuticals, Viatris, RemeGen, UCB Pharma, Genentech, Bristol Myers Squibb, AbbVie, among others.
Multiple Sclerosis Market
Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key multiple sclerosis companies, including Novartis, Sanofi, AB Science, Roche, Clene Nanomedicine, InnoCare Pharma, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
SOURCE DelveInsight Business Research, LLP